Clinical • Trial completion date • Trial termination • Trial primary completion date • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • MSLN (Mesothelin)
|
ALK rearrangement • MSLN overexpression
|
pemlimogene merolisbac (JNJ-64041757)